Antibodies to CTLA-4 and PD-1/PD-L1 have recently been identified for their role in the treatment of a variety of malignancies, including metastatic melanoma [4,9] and nivolumab for non-small cell lung cancer (NSCLC) [10,11]. This evidence concerns the gene CTLA4 and metastatic melanoma.